Abstract
Globally, chronic obstructive pulmonary disease (COPD) is a major cause of significant morbidity and mortality, and is now the third leading cause of death in the United States. Over the past 15 years there has been a surge of bench and translational research regarding the genetics and pathogenesis of COPD, and several large-scale clinical trials have introduced new treatment paradigms for COPD. Current research also demonstrates that COPD is not just a lung disease and that there are several potential extrapulmonary manifestations and comorbidities that should be evaluated and treated when one identifies an individual as having COPD.
Copyright © 2011. Published by Elsevier Inc.
MeSH terms
-
Algorithms
-
Anti-Inflammatory Agents / therapeutic use
-
Bronchodilator Agents / administration & dosage
-
Comorbidity
-
Disease Progression
-
Drug Therapy, Combination
-
Glucocorticoids / administration & dosage
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
-
Lung Transplantation
-
Pneumonectomy
-
Practice Guidelines as Topic
-
Pulmonary Disease, Chronic Obstructive* / blood
-
Pulmonary Disease, Chronic Obstructive* / diagnosis
-
Pulmonary Disease, Chronic Obstructive* / epidemiology
-
Pulmonary Disease, Chronic Obstructive* / rehabilitation
-
Risk Factors
-
Spirometry
-
Treatment Outcome
Substances
-
Anti-Inflammatory Agents
-
Bronchodilator Agents
-
Glucocorticoids
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors